SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today announced the pricing of its upsized
Second clinical-stage asset generated from the company’s proprietary library of SIRP-targeted antibodies SOUTH SAN FRANCISCO, CA, Sept. 10, 2026 – Electra Therapeutics, a clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of
SOUTH SAN FRANCISCO, CA, Sept. 9, 2026 – Electra Therapeutics, a clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today announced the promotion of Chris Clark, CFA, to Chief Financial Officer.
SOUTH SAN FRANCISCO, CA, May 5, 2026 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced dosing of the first patient in a Phase 1 study of ipsoprubart (ELA026) in patients with T cell
SOUTH SAN FRANCISCO, CA, January 5, 2026 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced that it will present at the 44th annual J.P. Morgan Healthcare Conference, taking place January
